Floatz logo

Tetanus-Cmv Fusion Peptide Vaccine

Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)

City of Hope Medical CentervaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort.

Asset / SponsorPhaseRating
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
Cytarabine
Alice Mims
Phase 3BBB
Idarubicin
Bruno C. Medeiros
Phase 2BBB
Etoposide
Alice Mims
Phase 3BBB

View all 50 →

Same molecule, other indications

Tetanus-Cmv Fusion Peptide Vaccine is also rated in:

acute myeloid leukemiaDormant
CC
Indicative · Phase 1
47 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CC
Indicative · Phase 1
47 / 100
View asset →
acute myeloid leukemia, del(5q31-q32)Dormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →